Cyclerion Therapeutics Inc (CYCN) — Cash Flow-to-Debt Ratio
Cyclerion Therapeutics Inc (CYCN) has a Cash Flow-to-Debt Ratio of -0.78x as of June 2026, meaning its operating cash flow of $-1.43 Million could theoretically repay -1% of its total liabilities ($1.84 Million) in one year. See Cyclerion Therapeutics Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cyclerion Therapeutics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Cyclerion Therapeutics Inc across 10 annual periods. For the full cash flow conversion analysis, see Cyclerion Therapeutics Inc (CYCN) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Cyclerion Therapeutics Inc (2016–2025)
Year-by-year debt coverage analysis for Cyclerion Therapeutics Inc. Check CYCN cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.68x | $-3.31 Million | $900.00K | ▲ +38.4% |
| 2024 | -5.98x | $-4.33 Million | $725.00K | ▲ +41.3% |
| 2023 | -10.18x | $-21.25 Million | $2.09 Million | ▼ -91.3% |
| 2022 | -5.32x | $-40.61 Million | $7.63 Million | ▼ -61.6% |
| 2021 | -3.29x | $-36.52 Million | $11.09 Million | ▼ -154.0% |
| 2020 | -1.30x | $-72.49 Million | $55.88 Million | ▼ -12.6% |
| 2019 | -1.15x | $-102.22 Million | $88.75 Million | ▲ +78.9% |
| 2018 | -5.46x | $-97.50 Million | $17.85 Million | ▲ +5.6% |
| 2017 | -5.79x | $-81.22 Million | $14.04 Million | ▼ -23.4% |
| 2016 | -4.69x | $-49.87 Million | $10.64 Million | — |